By Staff
Monday, May 13, 2024 12:21 AM
EMERYVILLE, Calif.—
NovaBay Pharmaceuticals, Inc., a developer of eyecare, skin care and wound care products, has reported its financial results for the three months ended March 31, 2024. Net product sales for the first quarter of 2024 were $2.6 million
By Staff
Monday, May 13, 2024 12:18 AM
VANCOUVER, British Columbia—
KITS Eyecare Ltd., a leading vertically integrated eyecare provider, has reported its results for the first quarter ended March 31, 2024. Revenue increased by 26 percent to $34.8 million.
By Staff
Monday, May 13, 2024 12:15 AM
ALPHARETTA, Ga.—
Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, has reported financial results for the first quarter ended March 31, 2024.
By Staff
Friday, May 10, 2024 12:27 AM
NEW YORK—
Warby Parker Inc. (NYSE: WRBY), has announced financial results for the first quarter ended March 31, 2024. Net revenue increased $28.0 million, or 16.3 percent, to $200.0 million, as compared with the prior-year period. The company also announced that average revenue per customer increased 9.6 percent year-over-year to $296 with increased active customer growth of 3.2 percent to 2.36 million.
By Staff
Friday, May 10, 2024 12:24 AM
LONGARONE and MILAN, Italy—The board of directors of
Marcolin approved the economic and financial results of the group as of March 31, 2024. In the first three months of 2024, Marcolin has continued to consolidate its performances, in line with the results registered in 2023, carrying out its growth path undertaken in recent years.
By Staff
Friday, May 10, 2024 12:15 AM
IRVINE, Calif.—
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, has announced financial results for the first quarter ended March 31, 2024.
By Staff
Thursday, May 9, 2024 12:27 AM
DULUTH, Ga.—
National Vision Holdings, Inc. (NASDAQ: EYE), one of the largest optical retail companies in the U.S., reported its financial results for the first quarter ended March 30, 2024. Net revenue increased 4.2 percent to $542.5 million compared with the first quarter of 2023 and was primarily driven by growth from new store sales, higher revenue from the company’s AC Lens business, and the effect of unearned revenue compared with the prior-year period. Net revenue includes a 0.5 percent impact from the timing of unearned revenue in the current-year period compared with the prior-year period, according to an announcement from the company.
By Staff
Thursday, May 9, 2024 12:21 AM
LAKE FOREST, Calif.—
STAAR Surgical Company, a developer, manufacturer and marketer of the EVO family of implantable collamer lenses (EVO ICL) for myopia, astigmatism and presbyopia, has reported financial results for the first quarter ended March 29, 2024.
By Staff
Thursday, May 9, 2024 12:18 AM
JENA, Germany—
Carl Zeiss Meditec AG reported revenue of approximately €947.2 million in the first six months of fiscal year 2023/24 compared with prior year's €974.5 million, a decrease in revenue of 2.8 percent.
By Staff
Wednesday, May 8, 2024 12:27 AM
PADUA—The board of directors of
Safilo Group S.p.A. yesterday reviewed and approved Q1 2024 economic and financial key performance indicators, according to an announcement from the company. Angelo Trocchia, Safilo’s chief executive officer, said, “In a business environment which is still complex and uncertain, it was again a positive start to the year for our European business, supported by the brilliant growth of Carrera, which has made its debut in our main markets with a brand new women's collection that is gathering excellent feedback, and David Beckham, which continued to register strong progress in the global premium segment. In North America, sales were affected by a subdued winter season for the sports business and a wholesale eyewear market that remained weak in the contemporary segment, while the direct-to-consumer channel of both Blenders and Smith continued to grow nicely.
By Staff
Wednesday, May 8, 2024 12:21 AM
ALISO VIEJO, Calif.—
RxSight, Inc., an ophthalmic medical device company specializing in adjustable intraocular lenses, has reported financial results for the three months ended March 31, 2024.
By Staff
Tuesday, May 7, 2024 12:18 AM
ST. LOUIS—
EyeCare Partners LLC, a leading provider of clinically integrated eyecare, has announced it has closed a follow-on debt exchange with holders of its existing term loans following an initial debt exchange that closed in April.
By Staff
Monday, May 6, 2024 12:18 AM
MENLO PARK, Calif.—
Sight Sciences, Inc., an eyecare technology company, reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full-year 2024.
By Staff
Friday, May 3, 2024 12:24 AM
ALISO VIEJO, Calif.—
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has announced financial results for the first quarter ended March 31, 2024.
By Staff
Thursday, May 2, 2024 12:27 AM
VAUGHAN, Ontario—
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, has announced its first-quarter 2024 financial results. The company reported that revenue grew 18 percent (20 percent on a constant currency basis) compared with the first quarter of 2023, driven by growth across all business segments. The company also raised full-year 2024 constant currency revenue growth guidance to 13 percent to 15 percent and the full-year revenue range to between $4.600 billion and $4.700 billion.